21st Austria weekly - Marinomed Bawag Kapsch TrafficCom 17/10/2023 [pic1]Marinomed: Marinomed Biotech AG has taken steps to further increase the flexibility of its corporate financing. agreed on an adjustment Convertible Notes Funding Program running since October 2021 initial maturity September 2023 and extension until 2024 with Swiss investment company Nice & Green S.A. So far 50% original program volume €5.4 million in convertible bonds have been issued converted into ordinary shares Marinomed.
EQS-News: Marinomed Biotech AG / Key word(s): BondMarinomed Biotech AG resumes Nice & Green Convertible Notes Funding Program with reduced volume 17.10.2023 / 07:45 CET/CESTThe issuer is solely responsible for the content of this announcement.Marinomed Biotech AG resumes Nice & Green Convertible Notes Fundi.
EQS-News: Marinomed Biotech AG resumes Nice & Green Convertible Notes Funding Program with reduced volume finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.
EQS-News: Marinomed Biotech AG / Key word(s): PatentMarinomed Biotech AG: Marinomed Biotech receives US Patent approval for the Marinosolv® technology and invests in a series of new patents 27.12.2022 / 07:45 CET/CESTThe issuer is solely responsible for the content of this announcement.Marinomed Biotech receives US.